AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Study Overview: AstraZeneca is conducting a Phase I/IIa clinical study titled ‘A Phase I/IIa Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD7789, an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Participants With Advanced or Metastatic Solid Tumors.’ The study aims to assess the safety and efficacy of AZD7789 in treating advanced solid tumors, marking a significant step in cancer treatment innovation.
Intervention/Treatment: The study tests AZD7789, an experimental anti-PD-1 and anti-TIM-3 bispecific antibody, administered intravenously. The drug is designed to target and treat advanced solid tumors, potentially offering a new therapeutic option for patients.
Study Design: This interventional study is randomized and follows a sequential intervention model. It is open-label, meaning both researchers and participants know the treatment being administered. The primary purpose is treatment-focused, with two parts: dose escalation (Part A) and dose expansion (Part B).
Study Timeline: The study began on September 28, 2021, with its primary completion and estimated completion dates yet to be announced. The latest update was submitted on July 7, 2025, indicating ongoing progress and data collection.
Market Implications: The ongoing study of AZD7789 could positively influence AstraZeneca’s stock performance by showcasing its commitment to innovative cancer treatments. Success in this study may enhance investor confidence and position AstraZeneca favorably against competitors in the oncology sector.
The study is currently active but not recruiting, with further details available on the ClinicalTrials portal.